Cargando…
Omalizumab for the Treatment of Chronic Spontaneous Urticaria: Association Between Body Mass Index and Outcome
INTRODUCTION: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. OBJECTIVES: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic spontaneous urticaria. METHODS: A retrospective data...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mattioli 1885
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681238/ https://www.ncbi.nlm.nih.gov/pubmed/36534565 http://dx.doi.org/10.5826/dpc.1204a148 |